Cybin Inc
CYBN6.000USD
0.000
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
138.20MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cybin Inc Unternehmen
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Unternehmensinformationen
BörsenkürzelCYBN
Name des UnternehmensCybin Inc
IPO-datumJan 05, 2018
CEOMr. Eric How-Lun So
Anzahl der mitarbeiter50
WertpapierartOrdinary Share
GeschäftsjahresendeJan 05
Addresse100 King Street West
StadtTORONTO
BörseAequitas NEO-L
LandCanada
PostleitzahlM5X 1C9
Telefon19087648385
Websitehttps://www.cybin.com
BörsenkürzelCYBN
IPO-datumJan 05, 2018
CEOMr. Eric How-Lun So
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
405.35K
+0.54%
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President, Interim Chief Executive Officer
Executive Chairman of the Board, President, Interim Chief Executive Officer
311.12K
-97.37%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Mr. Greg Cavers
Mr. Greg Cavers
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mark Lawson
Mr. Mark Lawson
Independent Director
Independent Director
--
--
Mr. Aaron Bartlone
Mr. Aaron Bartlone
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Eric Hoskins
Dr. Eric Hoskins
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
405.35K
+0.54%
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President, Interim Chief Executive Officer
Executive Chairman of the Board, President, Interim Chief Executive Officer
311.12K
-97.37%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Sep 3
Aktualisiert: Wed, Sep 3
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Nivorozhkin (Alex)
20.85%
Tang Capital Management, LLC
7.27%
Point72 Asset Management, L.P.
6.38%
Deep Track Capital LP
6.07%
Global X Investments Canada Inc.
5.32%
Andere
54.12%
Aktionäre
Aktionäre
Anteil
Nivorozhkin (Alex)
20.85%
Tang Capital Management, LLC
7.27%
Point72 Asset Management, L.P.
6.38%
Deep Track Capital LP
6.07%
Global X Investments Canada Inc.
5.32%
Andere
54.12%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
34.68%
Hedge Fund
25.34%
Investment Advisor
7.15%
Investment Advisor/Hedge Fund
5.63%
Private Equity
0.45%
Research Firm
0.35%
Bank and Trust
0.06%
Andere
26.34%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
203
58.05M
152.46%
-77.16M
2025Q1
209
57.54M
286.29%
-78.15M
2024Q4
205
59.72M
283.54%
-81.34M
2024Q3
197
62.29M
285.74%
-324.75M
2024Q2
204
344.93M
166.65%
-48.46M
2024Q1
195
368.84M
163.99%
+249.67M
2023Q4
177
108.66M
110.45%
+25.70M
2023Q3
166
58.71M
23.51%
+14.44M
2023Q2
156
50.00M
26.24%
+942.60K
2023Q1
152
52.80M
27.84%
+4.58M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Nivorozhkin (Alex)
5.25M
24.3%
+280.74K
+5.65%
Mar 31, 2024
Tang Capital Management, LLC
1.83M
8.47%
+500.00K
+37.59%
Mar 31, 2025
Point72 Asset Management, L.P.
1.33M
6.14%
+508.22K
+62.13%
May 20, 2025
Deep Track Capital LP
1.53M
7.08%
--
--
Mar 31, 2025
Global X Investments Canada Inc.
1.34M
6.2%
-213.08K
-13.73%
Feb 29, 2024
Tziras (George)
1.29M
5.99%
--
--
Jul 24, 2024
Bartlone (Aaron Frank)
901.07K
4.17%
+200.00K
+28.53%
Jun 28, 2024
Rosalind Advisors, Inc.
810.92K
3.75%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
734.39K
3.4%
+1.00
+0.00%
Mar 31, 2025
Fahel (Gabriel)
287.70K
1.33%
+700.00
+0.24%
Mar 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Datum
Art
Verhältnis
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
